Japan's top drugmaker appoints first foreign boss

November 30, 2013

Japan's top drugmaker said Saturday it had picked a GlaxoSmithKline executive as its next president in a rare example of overseas head-hunting by a major Japanese firm.

The board of directors at Takeda Pharmaceutical, which has been active in foreign acquisitions in recent years, approved 47-year-old French Christophe Weber, as and candidate as the next chief executive.

He will be the first non-Japanese chief in 230 years of history at the company based in western Japan's Osaka.

Weber will join Takeda to take the role of chief operating officer by April 2014 and is expected to become president upon approval at a general meeting of shareholders in June, Takeda said in a statement.

Current president and chief executive Yasuchika Hasegawa is expected to become chairman and chief executive.

"We have extremely high expectations for Mr Weber's contributions to further enhance and accelerate the implementation of Takeda's global strategy," Hasegawa said in the statement.

Weber, educated at the University of Lyon, has held various positions at GSK in Europe, United States and the Asia-Pacific region.

Takeda operates in more than 70 countries after its 2011 acquisition of major Swiss rival Nycomed for $14 billion.

There are only a handful of foreign chiefs at leading Japanese companies. Carlos Ghosn, the of French auto group Renault who also heads Nissan Motor, is one of the most prominent.

Explore further: Japanese firm buys US pharmaceutical company

Related Stories

Japanese firm buys US pharmaceutical company

October 5, 2012
(AP)—A Japanese pharmaceutical company is acquiring LigoCyte Pharmaceuticals in a $60 million deal to expand its vaccine division, Takeda Pharmaceutical Co. announced.

Drugs firm GSK eyes India acquisitions: chief executive

October 3, 2011
British drugmaker GlaxoSmithKline is in the market to buy assets in India at a total cost of up to $2.0 billion (1.5 billion euros), its chief executive said in an interview published on Monday.

US drug firm Mylan to buy Indian firm for $1.6 bn

February 27, 2013
US generic drugs specialist Mylan said Thursday it would buy a unit of India's pharma firm Strides Arcolab for $1.6 billion, boosting its presence in the high-growth injectable drugs market.

Siemens appoints board replacement for Ackermann

September 18, 2013
German engineering company Siemens is appointing the co-CEO of business software maker SAP to its board of directors to replace Josef Ackermann, who resigned in the wake of the board's decision to push out chief executive ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.